How many SAB Biotherapeutics (SABS) RSU-related shares remain for Alexandra Kropotova after this event?

A footnote states her position includes 38,402 shares of common stock and 3,433 shares of common stock that remain subject to vesting of RSUs under the company’s 2021 Equity Incentive Plan.

SAB Biotherapeutics CMO has 473 shares withheld

Q: Was Alexandra Kropotova’s SAB Biotherapeutics (SABS) Form 4 transaction a market sale?

No. The Form 4 states that 473 shares were withheld to satisfy tax withholding requirements upon vesting of restricted stock units, which is a compensation-related disposition rather than an open-market sale.

Q: What role does Alexandra Kropotova hold at SAB Biotherapeutics (SABS)?

Alexandra Kropotova is identified in the filing as the Chief Medical Officer of SAB Biotherapeutics, Inc.

Q: Does the SAB Biotherapeutics (SABS) Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that the transaction was made under a Rule 10b5-1 trading plan.

Chief Medical Officer Alexandra Kropotova reported a routine tax-withholding share disposition related to RSU vesting at SAB Biotherapeutics.

Available on EDGAR 09/18/2026 - 04:15 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:15 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. (SABS) reported that Chief Medical Officer Alexandra Kropotova had 473 shares of common stock withheld on September 17, 2026 to satisfy tax withholding requirements upon vesting of restricted stock units. After this tax-withholding disposition, she holds 41,853 shares directly, including vested and unvested RSU-related shares.

Insider Trade Summary

Tax Withholding: 473 shares

Tax Withholding 1 txn

Insider Kropotova Alexandra

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock ^{F1, F2, F3}	473	--	--

Holdings After Transaction: Common Stock — 41,853 shares (Direct)

Holdings Before and After: Common Stock, 42,326 to 41,853 shares (Direct)

Footnotes (3)

F1. Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").
F2. Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.
F3. Each RSU represents a contingent right to receive one share of Common Stock.

Key Figures

Shares withheld for taxes: 473 shares Shares held after transaction: 41,853 shares Vested common stock included: 38,402 shares +1 more

4 metrics

Shares withheld for taxes 473 shares Common stock withheld on September 17, 2026 to satisfy tax withholding on RSU vesting

Shares held after transaction 41,853 shares Direct ownership of SAB Biotherapeutics common stock after the September 17, 2026 disposition

Vested common stock included 38,402 shares Common stock included in post-transaction holdings as described in the footnote

Unvested RSU-related shares 3,433 shares Common stock subject to vesting of RSUs under the 2021 Equity Incentive Plan

Key Terms

restricted stock units, tax withholding requirements, 2021 Equity Incentive Plan

3 terms

restricted stock units financial

"withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding requirements financial

"withheld to statisfy tax withholding requirements on the vesting of the Issuer's"

2021 Equity Incentive Plan financial

"RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SAB Biotherapeutics (SABS) report for Alexandra Kropotova?

SAB Biotherapeutics reported that Chief Medical Officer Alexandra Kropotova had 473 shares of common stock withheld on September 17, 2026 to satisfy tax withholding requirements on vesting restricted stock units.

How many SAB Biotherapeutics (SABS) shares does Alexandra Kropotova hold after this Form 4 transaction?

After the reported tax-withholding disposition, Alexandra Kropotova directly holds 41,853 shares of SAB Biotherapeutics common stock, including shares from vested stock and unvested RSUs reported in the filing.

Was Alexandra Kropotova’s SAB Biotherapeutics (SABS) Form 4 transaction a market sale?

No. The Form 4 states that 473 shares were withheld to satisfy tax withholding requirements upon vesting of restricted stock units, which is a compensation-related disposition rather than an open-market sale.

What role does Alexandra Kropotova hold at SAB Biotherapeutics (SABS)?

Alexandra Kropotova is identified in the filing as the Chief Medical Officer of SAB Biotherapeutics, Inc.

Does the SAB Biotherapeutics (SABS) Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that the transaction was made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kropotova Alexandra

(Last)

(First)

(Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH

FLORIDA

33140

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/17/2026		F		473⁽¹⁾	D	⁽¹⁾	41,853⁽²⁾⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").

2. Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

3. Each RSU represents a contingent right to receive one share of Common Stock.

	/s/ Alexandra Kropotova	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR